ISRCTN17199301已完成未知
The effect of mirabegron, used for overactive bladder treatment, on female sexual function
Elpis Hospital0 个研究点目标入组 70 人开始时间: 2017年10月20日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
2018 results in https://www.ncbi.nlm.nih.gov/pubmed/29940933
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Women over the age of 18 being in a sexually active relationship suffering from OAB for a minimal period of 3 months
- •2. None of the latter women received previously treatment for OAB
- •3. Willing of women to comply with the protocol and the capability to complete the voiding diaries and the questionnaires without assistance
排除标准
- •1. Clinically significant stress urinary incontinence
- •2. Neurogenic bladder and urinary retention or are at risk for these conditions
- •3. Women with a history of pelvic muscle training programs will be excluded because it is accepted that pelvic floor muscle exercises improve female sexual function
- •4. Women who state that they are not sexually active will be excluded from further analysis
- •5. Women who consider that there is no need for long-term treatment for OAB or are afraid of regimen’s adverse effects are included in control group
研究者
相似试验
Unknown
4 期
Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's DiseaseOveractive BladderParkinson DiseaseNCT03412513Seoul National University Hospital144
已完成
4 期
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive BladderUrge IncontinenceOveractive Bladder (OAB)NCT04562090Astellas Pharma China, Inc.249
Unknown
3 期
Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in TaiwanOveractive Bladder SyndromeNCT03044912Buddhist Tzu Chi General Hospital574
已完成
3 期
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in TaiwanUrinary IncontinenceOveractive Bladder SyndromeNCT03059134Buddhist Tzu Chi General Hospital168
已完成
4 期
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)Overactive Bladder (OAB)NCT02216214Astellas Pharma Global Development, Inc.888